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Background
IDS is mainly a sexually transmitted infection. Blocking
sexual transmission of HIV requires developing a prophy-
lactic vaccine that promotes a protective mucosal
response in genital and intestinal compartments for pre-
venting initial HIV transmission events. Induction of such
long lasting mucosal response requires developing a
mucosal vaccine strategy.
Methods
We have developed a mucosal vaccine candidate based on
two complementary conserved gp41 subunit antigens- a
trimeric recombinant gp41 deleted in known immuno-
dominant regions (rGp41) and the 35 amino acid peptide
P1, this later adopting the 3D conformation of the gp41
MPER and target of HIV-neutralizing IgA in highly
exposed but persistently seronegative individuals- for
focusing the immune response on relevant neutralizing
epitopes. Gp41 subunit antigens are grafted on virosomes,
a market-approved vaccine carrier with intrinsic adjuvant
properties. Female Macaca mulata were immunized 4
times with both rGp41- and P1 peptide-virosomes, using
either the sole intra-muscular or the combined intra-mus-
cular/intra nasal routes. Five weeks post-vaccination, ani-
mals were challenged 13 times intra-vaginally with low
dose of SHIV162p3 at a biweekly frequency.
Results
Up to 13 weeks post-challenge, 5/5 animals vaccinated by
the combined intra muscular/intra nasal routes were fully
protected against SHIV162p3 (undetectable viremia, anti-
HIV IgG seronegativity), as compared to the 6/6 infected
control group, or the 5/6 infected animals vaccinated by
only the intra muscular route. Protection was correlated to
gp41-specific IgA in vaginal secretions with in vitro neu-
tralizing activities against transcytosis and CD4+ cell
infection.
Conclusion
Mucosal IgA specific for gp41 could block the initial steps
of HIV transmission at the female genital tract, by block-
ing either HIV entry by transcytosis in the epithelium or
infection of immune cells in the submucosa. Virosome-
gp41 subunit vaccines raising a mucosal antibody
response against key epitopes of gp41 that control HIV
infection and transcytosis could provides a mucosal pro-
tection against sexual HIV transmission.
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